Clearmind reports additional positive safety data for CMND-100 in alcohol use disorder

Clearmind Medicine Inc. (CMND) — Clearmind Medicine announced additional topline safety results from the second cohort of its Phase I/IIa trial of CMND-100, a non-hallucinogenic oral candidate for alcohol use disorder, reporting no serious adverse events and good tolerability after six additional patients completed treatment.

The multinational study is run with partners including Yale and Johns Hopkins. The favorable safety profile positioned the program to advance to its next stage.

Source: globenewswire.com

For the rest of that week's sector news, read our week in review.